Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system.

Nie ZL, Pan YQ, He BS, Gu L, Chen LP, Li R, Xu YQ, Gao TY, Song GQ, Hoffman AR, Wang SK, Hu JF.

Mol Cancer. 2012 Nov 21;11:86. doi: 10.1186/1476-4598-11-86.

2.

Gene therapy for cancer through adenovirus vector‑mediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting.

Pan Y, He B, Lirong Z, Nie Z, Chen L, Gu L, Hoffman AR, Wang S, Hu J.

Oncol Rep. 2013 Oct;30(4):1814-22. doi: 10.3892/or.2013.2646. Epub 2013 Jul 30.

3.

[Effect of recombinant adenovirus Ad-DT-A in targeted therapy for malignant cancer cell lines with loss of IGF2 imprinting].

Pan YQ, He BS, Zhu C, Qu LL, Xu XF, Wang SK.

Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):816-21. Chinese.

PMID:
22335945
4.

Targeted tumor gene therapy based on loss of IGF2 imprinting.

Pan Y, He B, Li T, Zhu C, Zhang L, Wang B, Xu Y, Qu L, Hoffman AR, Wang S, Hu J.

Cancer Biol Ther. 2010 Aug 1;10(3):290-8. Epub 2010 Aug 21.

5.

Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the insulin-like growth factor 2 imprinting.

Sun H, Pan Y, He B, Deng Q, Li R, Xu Y, Chen J, Gao T, Ying H, Wang F, Liu X, Wang S.

Int J Oncol. 2015 Apr;46(4):1759-67. doi: 10.3892/ijo.2015.2852. Epub 2015 Jan 26.

PMID:
25625919
6.

Gene therapy for colorectal cancer by adenovirus-mediated siRNA targeting CD147 based on loss of the IGF2 imprinting system.

Pan Y, He B, Chen J, Sun H, Deng Q, Wang F, Ying H, Liu X, Lin K, Peng H, Xie H, Wang S.

Int J Oncol. 2015 Nov;47(5):1881-9. doi: 10.3892/ijo.2015.3181. Epub 2015 Sep 23.

PMID:
26397886
7.

Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.

Wang H, Wei F, Li H, Ji X, Li S, Chen X.

Int J Mol Med. 2013 Feb;31(2):377-85. doi: 10.3892/ijmm.2012.1197. Epub 2012 Nov 29.

PMID:
23229955
8.

The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.

Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, Wang YG, Jia XY, Liu XY.

Cancer Biol Ther. 2010 Aug 1;10(3):242-50. Epub 2010 Aug 10.

PMID:
20574150
9.

Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.

He G, Lei W, Wang S, Xiao R, Guo K, Xia Y, Zhou X, Zhang K, Liu X, Wang Y.

J Cancer Res Clin Oncol. 2012 Apr;138(4):657-70. doi: 10.1007/s00432-011-1138-2. Epub 2012 Jan 12.

PMID:
22237452
10.

Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2.

Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP.

Cancer Res. 2002 Nov 15;62(22):6442-6.

11.

Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.

Liu L, Wu W, Zhu G, Liu L, Guan G, Li X, Jin N, Chi B.

Int J Mol Med. 2012 Oct;30(4):747-54. doi: 10.3892/ijmm.2012.1077. Epub 2012 Jul 25.

PMID:
22842823
12.

HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.

Xu HN, Huang WD, Cai Y, Ding M, Gu JF, Wei N, Sun LY, Cao X, Li HG, Zhang KJ, Liu XR, Liu XY.

Mol Cancer. 2011 Nov 1;10:133. doi: 10.1186/1476-4598-10-133.

13.

Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.

Wang F, Wang Z, Tian H, Qi M, Zhai Z, Li S, Li R, Zhang H, Wang W, Fu S, Lu J, Rodriguez R, Guo Y, Zhou L.

Curr Gene Ther. 2012 Apr 1;12(2):67-76.

14.

A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.

Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.

Cancer Gene Ther. 2008 Mar;15(3):173-82. Epub 2007 Dec 21.

PMID:
18157145
16.

A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.

Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.

J Gene Med. 2006 Oct;8(10):1232-42.

PMID:
16900558
17.

Analysis of genomic imprinting of insulin-like growth factor 2 in colorectal cancer.

Takano Y, Shiota G, Kawasaki H.

Oncology. 2000 Sep;59(3):210-6.

PMID:
11053988
18.

Temporal stability and age-related prevalence of loss of imprinting of the insulin-like growth factor-2 gene.

Cruz-Correa M, Zhao R, Oviedo M, Bernabe RD, Lacourt M, Cardona A, Lopez-Enriquez R, Wexner S, Cuffari C, Hylind L, Platz E, Cui H, Feinberg AP, Giardiello FM.

Epigenetics. 2009 Feb 16;4(2):114-8. Epub 2009 Feb 27.

19.

A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.

Yamasaki Y, Tazawa H, Hashimoto Y, Kojima T, Kuroda S, Yano S, Yoshida R, Uno F, Mizuguchi H, Ohtsuru A, Urata Y, Kagawa S, Fujiwara T.

Eur J Cancer. 2012 Sep;48(14):2282-91. doi: 10.1016/j.ejca.2011.12.020. Epub 2012 Jan 13.

PMID:
22244827
20.

Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.

Zhai Z, Wang Z, Fu S, Lu J, Wang F, Li R, Zhang H, Li S, Hou Z, Wang H, Rodriguez R.

Gene Ther. 2012 Nov;19(11):1065-74. doi: 10.1038/gt.2011.180. Epub 2012 Jan 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk